Загрузка...

Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

BACKGROUND: The efficacy and safety of rituximab (RTX) on hemolytic anemia (HA) is unknown. Therefore we retrospectively analyze the efficacy and safety of RTX in autoimmune hemolytic anemia (AIHA) and microangiopathic hemolytic anemia (MAHA) from the previous literature. METHODS: Data in clinical t...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Exp Hematol Oncol
Главные авторы: Chao, Shih-Hsuan, Chang, Yuh-Lih, Yen, Jiin-Cherng, Liao, Hsien-Tzung, Wu, Tsai-Hung, Yu, Chia-Li, Tsai, Chang-Youh, Chou, Yueh-Ching
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2020
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7161265/
https://ncbi.nlm.nih.gov/pubmed/32322437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00163-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!